The phase 3 trial was designed to evaluate the effectiveness of switching to camizestrant in combination with a CDK 4/6 inhibitor after the emergence of an ESR1 mutation, a key driver of resistance to endocrine therapy, according to a Feb. 26 news release from the company.
The results showed a statistically significant improvement in progression-free survival. While secondary end points — including overall survival and time to second disease progression — remain under evaluation, initial data showed a trend toward improved outcomes with the camizestrant combination.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.